Emergent Biosolutions Inc (NYSE: EBS) kicked off on Monday, up 4.82%% from the previous trading day, before settling in for the closing price of $6.22. Over the past 52 weeks, EBS has traded in a range of $4.02-$15.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 469.57%. With a float of $51.92 million, this company’s outstanding shares have now reached $54.50 million.
Let’s determine the extent of company efficiency that accounts for 900 employees. In terms of profitability, gross margin is 31.6%, operating margin of -5.65%, and the pretax margin is -6.49%.
Emergent Biosolutions Inc (EBS) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Emergent Biosolutions Inc is 4.35%, while institutional ownership is 66.76%. The most recent insider transaction that took place on May 23 ’25, was worth 49,417. In this transaction Director of this company sold 7,844 shares at a rate of $6.30, taking the stock ownership to the 86,431 shares. Before that another transaction happened on May 23 ’25, when Company’s Director proposed sale 7,844 for $6.30, making the entire transaction worth $49,409.
Emergent Biosolutions Inc (EBS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 469.57% per share during the next fiscal year.
Emergent Biosolutions Inc (NYSE: EBS) Trading Performance Indicators
Take a look at Emergent Biosolutions Inc’s (EBS) current performance indicators. Last quarter, stock had a quick ratio of 3.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.37. Likewise, its price to free cash flow for the trailing twelve months is 3.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.71, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach 1.25 in one year’s time.
Technical Analysis of Emergent Biosolutions Inc (EBS)
Looking closely at Emergent Biosolutions Inc (NYSE: EBS), its last 5-days average volume was 1.2 million, which is a jump from its year-to-date volume of 1.19 million. As of the previous 9 days, the stock’s Stochastic %D was 35.63%.
During the past 100 days, Emergent Biosolutions Inc’s (EBS) raw stochastic average was set at 32.34%, which indicates a significant decrease from 56.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.94% in the past 14 days, which was lower than the 92.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.78, while its 200-day Moving Average is $7.71. However, in the short run, Emergent Biosolutions Inc’s stock first resistance to watch stands at $6.75. Second resistance stands at $6.98. The third major resistance level sits at $7.28. If the price goes on to break the first support level at $6.22, it is likely to go to the next support level at $5.92. Now, if the price goes above the second support level, the third support stands at $5.69.
Emergent Biosolutions Inc (NYSE: EBS) Key Stats
The company with the Market Capitalisation of 353.89 million has total of 54,278K Shares Outstanding. Its annual sales at the moment are 1,044 M in contrast with the sum of -190,600 K annual income. Company’s last quarter sales were recorded 222,200 K and last quarter income was 68,000 K.
